Literature DB >> 10882402

Differential A(1)-adenosine receptor reserve for inhibition of cyclic AMP accumulation and G-protein activation in DDT(1) MF-2 cells.

S P Baker1, P J Scammells, L Belardinelli.   

Abstract

1. The A(1)-adenosine receptor (A(1)AdoR) reserve for N(6)-cyclopentyladenosine (CPA) mediated inhibition of (-)isoprenaline stimulated cyclic AMP accumulation and stimulation of [(35)S]-guanosine-5'-O-(thiotriphosphate) (GTPgammaS) binding, a measure of guanine nucleotide binding protein (G-protein) activation, was determined in DDT(1) MF-2 cells. 2. Inactivation of the A(1)AdoRs with the chemoreactive ligand 8-cyclopentyl-3-[3-[[4-(fluorosulphonyl)benzoyl]oxy]propyl]-1-p ropylx anthine (FSCPX) caused a progressive rightward shift of the concentration-response curves for CPA to inhibit cyclic AMP accumulation, with a maximum of 10 fold increase in the EC(50) value. In contrast, inactivation of A(1)AdoR's caused only a 1.7 fold rightward shift in the CPA concentration-response for stimulation of [(35)S]-GTPgammaS binding. 3. The A(1)AdoR occupancy-response relationship for CPA inhibition of cyclic AMP accumulation was hyperbolic with 43% receptor occupancy required to elicit the maximal response, i.e. a 57% A(1)AdoR reserve. In contrast, the A(1)AdoR occupancy-response relationship for CPA mediated stimulation of [(35)S]-GTPgammaS binding was linear indicating little or no receptor reserve for G-protein activation. The relationship between CPA stimulation of [(35)S]-GTPgammaS binding and cyclic AMP inhibition was also hyperbolic with 44% G-protein activation sufficient to cause maximal inhibition. 4. The data suggest that the A(1)AdoR reserve for CPA mediated inhibition of cyclic AMP accumulation occurs at the level of G-protein interaction with adenylyl cyclase. However, each A(1)AdoR appears to activate a constant fraction of the total G-protein population suggesting signal amplification at the receptor-G-protein level which may also contribute to the receptor reserve for CPA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882402      PMCID: PMC1572163          DOI: 10.1038/sj.bjp.0703405

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Existence of spare alpha 1-adrenoreceptors, but not alpha 2-adrenoreceptors, for respective vasopressor effects of cirazoline and B-HT 933 in the pithed rat.

Authors:  R R Ruffolo; E L Yaden
Journal:  J Cardiovasc Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.105

3.  Measurement of guanine nucleotide-binding protein activation by A1 adenosine receptor agonists in bovine brain membranes: stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding.

Authors:  A Lorenzen; M Fuss; H Vogt; U Schwabe
Journal:  Mol Pharmacol       Date:  1993-07       Impact factor: 4.436

4.  Evidence of spare A1-adenosine receptors in guinea pig atrioventricular node.

Authors:  D Dennis; K Jacobson; L Belardinelli
Journal:  Am J Physiol       Date:  1992-03

5.  Activation of pigeon erythrocyte membrane adenylate cyclase by guanylnucleotide analogues and separation of a nucleotide binding protein.

Authors:  T Pfeuffer; E J Helmreich
Journal:  J Biol Chem       Date:  1975-02-10       Impact factor: 5.157

6.  Purification and properties of the inhibitory guanine nucleotide-binding regulatory component of adenylate cyclase.

Authors:  G M Bokoch; T Katada; J K Northup; M Ui; A G Gilman
Journal:  J Biol Chem       Date:  1984-03-25       Impact factor: 5.157

7.  Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system.

Authors:  N Adham; B Ellerbrock; P Hartig; R L Weinshank; T Branchek
Journal:  Mol Pharmacol       Date:  1993-03       Impact factor: 4.436

8.  Spare receptors for beta-adrenoceptor-mediated positive inotropic effects of catecholamines in the human heart.

Authors:  L Brown; N M Deighton; S Bals; W Söhlmann; H R Zerkowski; M C Michel; O E Brodde
Journal:  J Cardiovasc Pharmacol       Date:  1992-02       Impact factor: 3.105

9.  Stimulation of adenosine A1 receptors and bradykinin receptors, which act via different G proteins, synergistically raises inositol 1,4,5-trisphosphate and intracellular free calcium in DDT1 MF-2 smooth muscle cells.

Authors:  P Gerwins; B B Fredholm
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

10.  Substituted 1,3-dipropylxanthines as irreversible antagonists of A1 adenosine receptors.

Authors:  P J Scammells; S P Baker; L Belardinelli; R A Olsson
Journal:  J Med Chem       Date:  1994-08-19       Impact factor: 7.446

View more
  8 in total

1.  Tonic activity of the rat adipocyte A1-adenosine receptor.

Authors:  Hui-Xiu Liang; Luiz Belardinelli; Mark J Ozeck; John C Shryock
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Adenosine A(1) receptor agonist N(6)-cyclohexyl-adenosine induced phosphorylation of delta opioid receptor and desensitization of its signaling.

Authors:  Yun Cheng; Yi-min Tao; Jian-feng Sun; Yu-hua Wang; Xue-jun Xu; Jie Chen; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-06-21       Impact factor: 6.150

Review 3.  Therapeutic receptor targets of ischemic preconditioning.

Authors:  Ryan M Fryer; John A Auchampach; Garrett J Gross
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

4.  A1 and A2A adenosine receptor modulation of alpha 1-adrenoceptor-mediated contractility in human cultured prostatic stromal cells.

Authors:  A Preston; M Frydenberg; J M Haynes
Journal:  Br J Pharmacol       Date:  2004-01       Impact factor: 8.739

5.  Sex differences in the Nociceptin/Orphanin FQ system in rat spinal cord following chronic morphine treatment.

Authors:  Yong Zhang; Courtney L Donica; Kelly M Standifer
Journal:  Neuropharmacology       Date:  2012-05-02       Impact factor: 5.250

Review 6.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

7.  Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor.

Authors:  James J Lu; Willma E Polgar; Anika Mann; Pooja Dasgupta; Stefan Schulz; Nurulain T Zaveri
Journal:  Mol Pharmacol       Date:  2021-05-06       Impact factor: 4.054

8.  FSCPX, a Chemical Widely Used as an Irreversible A₁ Adenosine Receptor Antagonist, Modifies the Effect of NBTI, a Nucleoside Transport Inhibitor, by Reducing the Interstitial Adenosine Level in the Guinea Pig Atrium.

Authors:  Tamas Erdei; Adrienn Monika Szabo; Nora Lampe; Katalin Szabo; Rita Kiss; Judit Zsuga; Csaba Papp; Akos Pinter; Andras Jozsef Szentmiklosi; Zoltan Szilvassy; Bela Juhasz; Rudolf Gesztelyi
Journal:  Molecules       Date:  2018-08-30       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.